|
1
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cully M, You H, Levine AJ and Mak TW:
Beyond PTEN mutations: the PI3K pathway as an integrator of
multiple inputs during tumorigenesis. Nat Rev Cancer. 6:184–192.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Karakas B, Bachman KE and Park BH:
Mutation of the PIK3CA oncogene in human cancers. Br J Cancer.
94:455–459. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liaw D, Marsh DJ, Li J, et al: Germline
mutations of the PTEN gene in Cowden disease, an inherited breast
and thyroid cancer syndrome. Nat Genet. 16:64–67. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Castellano E and Downward J: Role of RAS
in the regulation of PI 3-kinase. Curr Top Microbiol Immunol.
346:143–169. 2010.PubMed/NCBI
|
|
6
|
Chan SK, Gullick WJ and Hill ME: Mutations
of the epidermal growth factor receptor in non-small cell lung
cancer - search and destroy. Eur J Cancer. 42:17–23. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ross JS and Fletcher JA: The HER-2/neu
oncogene in breast cancer: prognostic factor, predictive factor,
and target for therapy. Stem Cells. 16:413–428. 1998. View Article : Google Scholar
|
|
8
|
Quintas-Cardama A and Cortes J: Molecular
biology of bcr-abl1-positive chronic myeloid leukemia. Blood.
113:1619–1630. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Alessi DR, James SR, Downes CP, et al:
Characterization of a 3-phosphoinositide-dependent protein kinase
which phosphorylates and activates protein kinase Balpha. Curr
Biol. 7:261–269. 1997. View Article : Google Scholar
|
|
10
|
Le Good JA, Ziegler WH, Parekh DB, Alessi
DR, Cohen P and Parker PJ: Protein kinase C isotypes controlled by
phosphoinositide 3-kinase through the protein kinase PDK1. Science.
281:2042–2045. 1998.
|
|
11
|
Chou MM, Hou W, Johnson J, et al:
Regulation of protein kinase C zeta by PI 3-kinase and PDK-1. Curr
Biol. 8:1069–1077. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Diaz-Meco MT, Lozano J, Municio MM, et al:
Evidence for the in vitro and in vivo interaction of Ras with
protein kinase C zeta. J Biol Chem. 269:31706–31710.
1994.PubMed/NCBI
|
|
13
|
Kuribayashi K, Nakamura K, Tanaka M, et
al: Essential role of protein kinase C zeta in transducing a
motility signal induced by superoxide and a chemotactic peptide,
fMLP. J Cell Biol. 176:1049–1060. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Valkov A, Sorbye SW, Kilvaer TK, et al:
The prognostic impact of TGF-beta1, fascin, NF-kappaB and PKC-zeta
expression in soft tissue sarcomas. PLoS One. 6:e175072011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu LR, Lv JQ, Jin LY, et al:
Over-expression of protein kinase Cisoforms (alpha, delta, theta
and zeta) in squamous cervical cancer. Neoplasma. 58:491–498.
2011.PubMed/NCBI
|
|
16
|
Yao S, Bee A, Brewer D, et al: PRKC-zeta
expression promotes the aggressive phenotype of human prostate
cancer cells and is a novel target for therapeutic intervention.
Genes Cancer. 1:444–464. 2010. View Article : Google Scholar
|
|
17
|
Schonwasser DC, Marais RM, Marshall CJ and
Parker PJ: Activation of the mitogen-activated protein
kinase/extracellular signal-regulated kinase pathway by
conventional, novel, and atypical protein kinase C isotypes. Mol
Cell Biol. 18:790–798. 1998.
|
|
18
|
Cohen EE, Lingen MW, Zhu B, et al: Protein
kinase C zeta mediates epidermal growth factor-induced growth of
head and neck tumor cells by regulating mitogen-activated protein
kinase. Cancer Res. 66:6296–6303. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun R, Gao P, Chen L, et al: Protein
kinase C zeta is required for epidermal growth factor-induced
chemotaxis of human breast cancer cells. Cancer Res. 65:1433–1441.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Datta K, Li J, Bhattacharya R, Gasparian
L, Wang E and Mukhopadhyay D: Protein kinase C zeta transactivates
hypoxia-inducible factor alpha by promoting its association with
p300 in renal cancer. Cancer Res. 64:456–462. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jhawer M, Goel S, Wilson AJ, et al: PIK3CA
mutation/PTEN expression status predicts response of colon cancer
cells to the epidermal growth factor receptor inhibitor cetuximab.
Cancer Res. 68:1953–1961. 2008. View Article : Google Scholar
|
|
22
|
Kim SH, Kim K, Kwagh JG, et al: Death
induction by recombinant native TRAIL and its prevention by a
caspase 9 inhibitor in primary human esophageal epithelial cells. J
Biol Chem. 279:40044–40052. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Saltz LB, Cox JV, Blanke C, et al:
Irinotecan plus fluorouracil and leucovorin for metastatic
colorectal cancer. Irinotecan Study Group. N Engl J Med.
343:905–914. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
de Thonel A, Bettaieb A, Jean C, Laurent G
and Quillet-Mary A: Role of protein kinase C zeta isoform in Fas
resistance of immature myeloid KG1a leukemic cells. Blood.
98:3770–3777. 2001.PubMed/NCBI
|
|
25
|
Leroy I, de Thonel A, Laurent G and
Quillet-Mary A: Protein kinase C zeta associates with death
inducing signaling complex and regulates Fas ligand-induced
apoptosis. Cell Signal. 17:1149–1157. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xin MG, Gao FQ, May WS, Flagg T and Deng
XM: Protein kinase C zeta abrogates the proapoptotic function of
bax through phosphorylation. J Biol Chem. 282:21268–21277. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Moscat J, Rennert P and Diaz-Meco MT:
PKCzeta at the crossroad of NF-kappaB and Jak1/Stat6 signaling
pathways. Cell Death Differ. 13:702–711. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Asanuma K, Kobayashi D, Furuya D, Tsuji N,
Yagihashi A and Watanabe N: A role for survivin in radioresistance
of pancreatic cancer cells. Jpn J Cancer Res. 93:1057–1062. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nakamura M, Tsuji N, Asanuma K, et al:
Survivin as a predictor of cis-diamminedichloroplatinum sensitivity
in gastric cancer patients. Cancer Sci. 95:44–51. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ceballos-Cancino G, Espinosa M, Maldonado
V and Melendez-Zajgla J: Regulation of mitochondrial
Smac/DIABLO-selective release by survivin. Oncogene. 26:7569–7575.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dohi T, Okada K, Xia F, et al: An IAP-IAP
complex inhibits apoptosis. J Biol Chem. 279:34087–34090. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dohi T, Xia F and Altieri DC:
Compartmentalized phosphorylation of IAP by protein kinase A
regulates cytoprotection. Mol Cell. 27:17–28. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Song Z, Yao X and Wu M: Direct interaction
between survivin and Smac/DIABLO is essential for the
anti-apoptotic activity of survivin during taxol-induced apoptosis.
J Biol Chem. 278:23130–23140. 2003. View Article : Google Scholar
|
|
34
|
Altieri DC: Survivin, cancer networks and
pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ye Q, Cai W, Zheng Y, Evers BM and She QB:
ERK and AKT signaling cooperate to translationally regulate
survivin expression for metastatic progression of colorectal
cancer. Oncogene. Apr 29–2013.(Epub ahead of print). View Article : Google Scholar
|
|
36
|
Diaz-Meco MT and Moscat J: The atypical
PKCs in inflammation: NF-kappaB and beyond. Immunol Rev.
246:154–167. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee WC, Berry R, Hohenstein P and Davies
J: siRNA as a tool for investigating organogenesis: The pitfalls
and the promises. Organogenesis. 4:176–181. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhao J, Tenev T, Martins LM, Downward J
and Lemoine NR: The ubiquitin-proteasome pathway regulates survivin
degradation in a cell cycle-dependent manner. J Cell Sci.
113:4363–4371. 2000.PubMed/NCBI
|
|
39
|
Abdulghani J and El-Deiry WS: TRAIL
receptor signaling and therapeutics. Expert Opin Ther Targets.
14:1091–1108. 2010. View Article : Google Scholar
|
|
40
|
Dimberg LY, Anderson CK, Camidge R,
Behbakht K, Thorburn A and Ford HL: On the TRAIL to successful
cancer therapy? Predicting and counteracting resistance against
TRAIL-based therapeutics. Oncogene. 32:1341–1350. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Reyland ME: Protein kinase C isoforms:
multi-functional regulators of cell life and death. Front Biosci.
14:2386–2399. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
42
|
Murray NR, Kalari KR and Fields AP:
Protein kinase Ciota expression and oncogenic signaling mechanisms
in cancer. J Cell Physiol. 226:879–887. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kuribayashi K and El-Deiry WS: Regulation
of programmed cell death by the p53 pathway. Adv Exp Med Biol.
615:201–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kuribayashi K, Finnberg N, Jeffers JR,
Zambetti GP and El-Deiry WS: The relative contribution of
pro-apoptotic p53-target genes in the triggering of apoptosis
following DNA damage in vitro and in vivo. Cell Cycle.
10:2380–2389. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kuribayashi K, Mayes PA and El-Deiry WS:
What are caspases 3 and 7 doing upstream of the mitochondria?
Cancer Biol Ther. 5:763–765. 2006. View Article : Google Scholar : PubMed/NCBI
|
